Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CGB-600 in non-segmental facial vitiligo
NCT07357870Phase 1Recruiting
- Sponsor
- CAGE Bio
- Start
- Jul 2025
- Primary completion
- Nov 2026
- Modality
- RNA Aptamers, DNA Aptamers
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in Vitiligo comparing CGB-600 gel with vehicle gel (2 arms). Primary endpoint: Overall Incidence of tabulated safety events at 24 weeks. Started Jul 2025; status: recruiting.
02
Drugs
CGB-600
03
Conditions
Vitiligo
Beyond the preview
Go deeper on NCT07357870.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07357870.